Summary: Cathepsin D serum mass concentrations were determined by enzyme immunoassay in patients with hepatocellular carcinoma (n = 51) and/or liver cirrhosis (n = 92) or benign steatosis (n = 16) and correlated with some biochemical and clinical properties of these diseases. Increased cathepsin D serum mass concentrations (P < 0.001) were observed in all these groups of patients as compared to normal subjects (n = 98). However, patients with steatosis had serum mass concentrations of this enzyme significantly lower (mean 2-3 fold) than those measured in cancer patients (P < 0.05) or cirrhotic patients (P < 0.001). Interestingly, significantly higher cathepsin D serum mass concentrations (mean + 62%) (P < 0.006) were determined in the cirrhosis group as compared to cancer patients. No correlation between cathepsin D and a number of clinical and biochemical properties examined, namely, α-foetoprotein, number of neoplastic lesions and tumour size in cancer patients or, ChildPugh grade of severity of cirrhosis and other enzymes of liver function tests in the cirrhotic group was found. The present data and those from other studies which indicate that cathepsin D may be involved in carcinogenesis suggest that this enzyme may be potentially useful as an additional biochemical marker to identify cirrhotic patients who may develop precancerous hepatic nodules.
cesses in vivo has still not been provided, a consistent bulk of clinical studies have shown that this enzyme is highly expressed, in terms of mass and/or catalytic activity concentrations, in tumour cells and tissues of a number of human neoplastic diseases as compared to their normal counterpart and that these levels may correlate, in some cases, with the malignant progression of these tumours (7) (8) (9) (10) (11) (12) (13) . In this context several studies have also shown increased cathepsin D catalytic activity concentrations in human liver tumours as compared to normal liver tissues (14) as well elevated plasma mass concentrations of this enzyme in patients with malignant and non-malignant liver diseases as compared to healthy subjects (15) . Interestingly, recent experimental in vitro and in vivo studies (16, 17) have evidenced in rat hepatoma cells altered intracellular processing and increased secretion of a precursor form of cathepsin D which appears to be endowed with mitogenic activity and a significant increase of the catalytic activity concentration of this enzyme in the ascites and in plasma of rats transplanted with Yoshida AH-130 hepatoma. An important consequence related to these phenomena may be, as suggested (14, 15, 18) , that cathepsin D produced in excess or unusually distributed at extracellular levels following these pathological processes, may be actively secreted into the bloodstream. Therefore, increased cathepsin D serum content may reflect the presence of neoplastic nodules in liver tissue or may also be related to the malignant transformation of cirrhosis, a non-neoplastic liver disease which may evolve in hepatocellular carcinoma (19) . In this latter case the pattern of serum levels of this enzyme may be useful as an additional biochemical marker to identify cirrhotic patients at risk to develop hepatocellular carcinoma. This finding may have clinical relevance as, to date, no serum marker including a-foetoprotein has been found specifically reliable for the early detection of precancerous lesions (20, 21) . On the basis of these considerations we have assessed cathepsin D serum mass concentrations in groups of patients with hepatocellular carcinoma and/or liver cirrhosis and evaluated its potential clinical interest in non-malignant and malignant liver diseases.
Materials and Methods

Patients
This study was undertaken on a total of 159 patients with malignant and non-malignant liver diseases whose clinical features are reported in table 1. Ninety-eight registered healthy blood donors of both sex were used as control. Diagnosis of hepatocellular carcinoma was established by ultrasonography and by histological findings following ultrasound-assisted fine-needle biopsy, evidence from positive diagnostic imaging and clinical and biochemical findings as well. Liver cirrhosis was diagnosed by histological findings and on the basis of unequivocal clinical and biochemical data. The Child-Pitgh classification (22) was used to evaluate the grade of severity of cirrhosis. Liver steatosis was diagnosed by histological findings. All subjects with steatosis had a positive serum test for hepatitis C virus. Immunoenzymatic and biochemical assays were performed on sera, previously stored at -80 °C, obtained from venous blood samples of patients and healthy blood donors.
Determination of cathepsin D serum mass concentrations
Cathepsin D concentrations were determined by a commercially available antibody-based immunoenzymatic kit (Ciba Corning Diagnostics, Alarneda, USA) in sera of both healthy subjects and patients and diluted 1 : 50 with the appropriate sample diluent included in the kit. The assay detected both precursors (procathepsin D, M r 52 000, M T 48 000) and mature (M r 34 000) forms of cathepsin D. The standard curve was linear from 0 up to 2.0 nmol/1. The minimum detectable concentration, according to the manufacturer, is 0.012 nmol/1. Mean cathepsin D serum mass concentrations in normal subjects, + 2-fold the standard deviation value or the highest serum value of the enzyme determined in healthy subjects, were taken as cut-off limits.
Determination of serum α-foetoprotpin and other biochemical tests α-Foetoprotein, the most sensitive and reliable serum marker for the diagnosis of hepatocellular carcinoma (23) , was determined in healthy subjects and in patients by a commercially available immunoluminometric based assay kit (Byk Sangtec, Milan, Italy). Normal range values, according to the manufacturer, were 0-8 kIU/1. Additionally, serum levels of 200 and 400 kIU/1 were used as cutoff values as these concentrations have been reported to be highly diagnostic for this tumour (20, 23, 24) . Furthermore, the following serum biochemical constituents were also assayed and their correlation with cathepsin D was assessed: alkaline phosphatase a P < 0.001 as compared to normal subjects; b P < 0.04 as compared to benign steatosis; c P < 0.006 as compared to hepatocellular carcinoma.
Results
Cathepsin D serum mass concentrations
the examined groups. No significant difference in the serum mass concentrations of this enzyme was observed between female and male normal subjects (tab. 2). Significantly higher cathepsin D serum mass concentrations (mean 4-6 fold) were determined either in cancer or cirrhotic patients as compared to normal subjects (P < 0.001). Interestingly, cathepsin D serum mass concentrations in cirrhotic patients were significantly higher (mean + 62%) than those measured in cancer patients (P = 0.006) (tab. 2). Statistically significant increased cathepsin D serum mass concentrations were also observed in subjects with steatosis as compared to normal subjects (P < O.O 1). However, these concentrations were, in turn, significantly lower (mean 2-3 fold) than those determined in the serum of cancer patients (P < 0.04) or patients from cirrhosis (P < 0.001) (tab. α-Foetoprotein serum concentrations α-Foetoprotein serum concentrations were markedly elevated (mean 842 fold) in cancer patients as compared to normal subjects or patients with cirrhosis (P < 0.001) (tab. 4). These concentrations were also significantly increased (mean 6 fold) in patients with cirrhosis as compared to normal subjects (P < 0.01). However, this phenomenon occurred at a very lessened extent as compared to cancer patients (tab. 4). The serum concentrations of this protein were significantly different in patients with tumour size larger or smaller than 3 cm (P < 0.05) and also significantly different in patients with single or multiple neoplastic lesions (P < 0.02). Rate of increased cathepsin D and α-foetoprotein in patients with hepatocellular carcinoma or cirrhosis Cathepsin D serum mass concentrations higher than the cut-off level of 24 nmol/1 (mean serum content in normal subjects + 2 standard deviations) were measured in 64.7% of cancer patients and in 88.0% of patients with cirrhosis (tab. 5). At a cut-off level of 50 nmol/1 (highest serum mass concentration measured in healthy subjects) this phenomenon was observed in 37.2% of cancer patients and in 61.9% of patients with cirrhosis (tab. 5). 
Discussion
Total cathepsin D serum mass concentrations (i. e. proenzyme + mature form) were observed to be significantly increased in patients with hepatocellular carcinoma and/or liver cirrhosis as compared to normal subjects. Interestingly, in cirrhotic patients these concentrations were significantly higher (mean + 62%) than those measured in cancer patients. Increased levels of this proteinase were also observed in subjects with benign steatosis, however these values were markedly (2-3 fold) lower than those measured in cancer patients and patients with cirrhosis. These data further confirm, in part, and extend some previous observations ofBrouillet et al. (15) and Zuhlsdorftf. al. (25) who found evidence of elevated mass concentrations of cathepsin D in the plasma or sera of patients with various liver diseases including hepatocellular carcinoma and cirrhosis. The increased serum content of cathepsin D observed in both cirrhotic and cancer patients may not only be the consequence of cytolytic processes which occur during the evolution of these pathological events but also related to an active secretion of this enzyme by intact hepatocytes, which contain most of the enzyme present in the human liver tissue (26) . This hypothesis, supported by previous observations of Ryvnyak et al. (18) who showed that, in rats with tetrahydrocarbon chloride-induced cirrhosis, cathepsin D was largely secreted by intact heptocytes and other connective tissue cells into the intercellular space during cirrhosis, is further suggested by the present data which showed the lack of a significant correlation between cathepsin D serum mass concentrations and some biochemical markers of cytolysis. As an altered secretion of this enzyme has been reported to be associated, at least in vitro, with some stages of oncogenic transformation in rat fibroblasts and with differentiation stages of some carcinoma cell lines (4, 27) , it would be conceivable to hypothesize that the increased serum levels of this proteinase in cirrhotic patients may also be associated with carcinogenetic processes which may occur during the evolution of this disease. Moreover, a number of experimental in vitro and in vivo investigations have shown that cathepsin D may induce tumour cell proliferation by acting as an autocrine mitogen (2, 5, 6) and that intraperitoneal injections of purified preparations of cathepsin D may stimulate DNA synthesis and mitosis in intact mouse liver (28, 29) . In addition, other studies have suggested that cathepsin D may be implicated in liver regeneration, remodelling and resorption of fibrous tissues in cirrhosis (18, 29, 30) as well as in the activation of latent precursor forms of other proteolytic enzymes, such as cathepsin B and L, involved in the degradation of collagen in fibrotic liver and in tumour invasion and metastasis (31, 32) . Therefore, these findings lead further to the hyopthesis that cathepsin D might be able to promote the malignant transformation of cirrhotic tissue. These observations may fit well with the higher cathepsin D serum mass concentrations observed in cirrhotic patients as compared to cancer patients. In conclusion, although these results indicate that cathepsin D does not seem to be more reliable than α-foetoprotein as a tool for the diagnosis of hepatocellular carcinoma, the increased serum levels of this enzyme, in addition to other proposed potential prognostic factors (33, 34) , may be of interest as an additional biochemical marker to identify patients with cirrhosis who may develop precancerous nodules. Prospective clinical investigations to better assess this hypothesis are currently in progress.
